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The recent recrudescence of Mycobacterium tuberculosis infection and the emergence of multidrug-resistant
strains have created an urgent need for new therapeutics against tuberculosis. The enzymes of the shikimate
pathway are attractive drug targets because this route is absent in mammals and, in M. tuberculosis, it is
essential for pathogen viability. This pathway leads to the biosynthesis of aromatic compounds, including
aromatic amino acids, and it is found in plants, fungi, bacteria, and apicomplexan parasites. The aroB-encoded
enzyme dehydroquinate synthase is the second enzyme of this pathway, and it catalyzes the cyclization of
3-deoxy-D-arabino-heptulosonate-7-phosphate in 3-dehydroquinate. Here we describe the PCR amplification
and cloning of the aroB gene and the overexpression and purification of its product, dehydroquinate synthase,
to homogeneity. In order to probe where the recombinant dehydroquinate synthase was active, genetic comple-
mentation studies were performed. The Escherichia coli AB2847 mutant was used to demonstrate that the
plasmid construction was able to repair the mutants, allowing them to grow in minimal medium devoid of
aromatic compound supplementation. In addition, homogeneous recombinant M. tuberculosis dehydroquinate
synthase was active in the absence of other enzymes, showing that it is homomeric. These results will support
the structural studies with M. tuberculosis dehydroquinate synthase that are essential for the rational design
of antimycobacterial agents.
Tuberculosis (TB) remains the leading cause of mortality
due to a bacterial pathogen, Mycobacterium tuberculosis, and
infects approximately one-third of the world’s population (10).
The World Health Organization has estimated that 9 million
people are infected per year, leading to 2 million deaths,
mainly in sub-Saharan Africa and Asia (39). The discovery of
the antibacterial and antituberculosis properties of streptomy-
cin, isoniazid, and pyrazinamide led to effective chemotherapy
that decreased the TB mortality rate worldwide (1). The later
introduction of ethionamide, rifampin, ethambutol, and cipro-
floxacin to the arsenal for TB treatment seemed to provide an
adequate number of effective antimicrobial agents. The re-
emergence of TB is basically a consequence of anthropic fac-
tors, such as the recent human immunodeficiency virus/AIDS
pandemic and the development of drug-resistant strains (stem-
ming from inappropriate treatments and/or patient noncom-
pliance) (13). Another contributing factor is the evolution of
multidrug-resistant TB, defined as TB caused by Mycobacte-
rium tuberculosis strains resistant to at least isoniazid and ri-
fampin, two first-line drugs used in the standard “short-course”
treatment of TB. More recently, the emergence of extensively
drug resistant TB (XDR-TB), defined as TB caused by isolates
resistant to isoniazid, rifampin, and at least three of the six
main classes of second-line drugs, has been reported (6).
XDR-TB is widespread, including occurrence in the United
States, where TB had been considered under control (12). The
worldwide occurrence of XDR-TB raises the prospect of vir-
tually incurable TB (12). There is thus an urgent need for new,
more effective drugs to improve the treatment of multidrug-
resistant TB and XDR-TB and to shorten the duration of TB
treatment.
The shikimate pathway (Fig. 1) is an attractive target for the
development of herbicides and antimicrobial agents because it
is essential for algae, higher plants, bacteria, and fungi but is
absent from mammals (4). The mycobacterial shikimate path-
way leads to the biosynthesis of precursors of aromatic amino
acids, naphthoquinones, menaquinones, and mycobactin (14).
Homologues to the seven enzymes of the shikimate pathway
have been identified in the genome sequence of M. tuberculosis
(9). This pathway has been shown to be essential for the via-
bility of M. tuberculosis (30). Accordingly, the essentiality of the
mycobacterial shikimate pathway and its absence from human
hosts indicate that the enzymes of this pathway represent prom-
ising targets for the development of nontoxic antimycobacterial
agents.
The gene (aroB; Rv2538c) encoding the dehydroquinate syn-
thase (DHQS; EC 4.6.1.3; systematic name, 3-deoxy-arabino-
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heptulosonate-7-phosphate phosphate-lyase) of the shikimate
pathway has been proposed to be present in M. tuberculosis by
sequence homology (9). DHQS catalyzes the conversion of
3-deoxy-D-arabino-heptulosonate 7-phosphate (DAHP) to 3-de-
hydroquinate, the first cyclic compound of this pathway (Fig. 2)
(34). DHQS utilizes a complex multistep mechanism that in-
cludes oxidation, -elimination, intramolecular aldol conden-
sation, and reduction (16). In Escherichia coli, the DHQS en-
zyme requires NAD as a cofactor, and a divalent cation, such
as Co2 or Zn2, is also needed (3, 25). Bacillus subtilis DHQS
has been purified in association with chorismate synthase and
NADPH-dependent flavin reductase, and although the choris-
mate synthase is required for B. subtilis DHQS activity, the
flavin reductase does not need to be present (20). In Neuros-
pora crassa and Aspergillus nidulans, the DHQS activity is the
FIG. 1. The mycobacterial shikimate pathway (the main trunk) leads to the biosynthesis of chorismic acid, a precursor of aromatic amino acids,
para-aminobenzoic acid, ubiquinone or coenzyme Q, naphthoquinones, menaquinones, and mycobactins.
FIG. 2. The chemical reaction catalyzed by DHQS.
VOL. 189, 2007 CHARACTERIZATION OF M. TUBERCULOSIS DHQS 6247
 o
n
 M
arch 15, 2017 by University of Queensland Library
http://jb.asm.org/
D
ow
nloaded from
 
first of five sequential steps of the shikimate pathway catalyzed
by a pentafunctional complex, encoded by arom, whose se-
quence has high similarity to the five monofunctional E. coli
counterparts, including DHQS (17, 35). Usually, DHQSs from
bacteria are significantly smaller than their fungal enzyme an-
alogues, and they also show significant structural divergence,
especially in the amino- and carboxy-terminal sequences.
To pave the way for structural and functional efforts cur-
rently under way in our laboratory on which to base the ratio-
nal design of antitubercular agents, the aroB gene from
M. tuberculosis strain H37Rv was PCR amplified, cloned, se-
quenced, and expressed, and a recombinant M. tuberculosis
DHQS protein was purified to homogeneity. Electrospray ion-
ization mass spectrometry (ESI-MS) analysis and N-terminal
sequencing were carried out to unequivocally identify the re-
combinant M. tuberculosis DHQS protein. Genetic comple-
mentation experiments using Escherichia coli mutant strains
lacking the aroB gene were carried out to confirm that recom-
binant M. tuberculosis DHQS was cloned in its functional form.
The availability of M. tuberculosis DHQS protein in large quan-
tities will allow enzyme kinetics and structural studies to be
undertaken in order to provide a framework to guide the
design of chemical compounds with antituberculosis activity.
MATERIALS AND METHODS
Amplification, cloning, and overexpression of the M. tuberculosis aroB gene.
Two oligonucleotides (5-GGCCATATGACCGATATCGGCGCACCCG-3
and 5-AGGATCCTCATGGGGCGCAAACTCCGGC-3) complementary to
the amino-terminal coding and carboxy-terminal noncoding strands of the M.
tuberculosis aroB gene (9) were synthesized to contain, respectively, NdeI and
BamHI restriction sites (underlined). These primers were used to PCR amplify
the aroB gene from M. tuberculosis H37Rv genomic DNA in the presence of 10%
dimethyl sulfoxide (DMSO). The PCR product (1,089 bp) was purified by elec-
trophoresis, digested with NdeI and BamHI (Boehringer Mannheim), and li-
gated into a pET23a() expression vector (Novagen) that had previously been
digested with the same restriction enzymes. The DNA sequence of the M.
tuberculosis aroB gene was determined in order to confirm the identity, integrity,
and absence of PCR-introduced mutations in the cloned gene. The recombinant
pET23a()::aroB plasmid was introduced into Escherichia coli BL21(DE3) (No-
vagen) electrocompetent cells and selected on LB agar plates containing 50 g
ml1 carbenicillin. LB medium (6 liters) containing carbenicillin was inoculated
with single colonies, which were grown for 20 h at 180 rpm and 37°C without
isopropyl--D-thiogalactopyranoside (IPTG) induction. Cells were harvested by
centrifugation at 4,000  g for 30 min at 4°C and were stored at 20°C. Soluble
and insoluble fractions were analyzed by 12% sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) (22).
Purification of M. tuberculosis DHQS. Approximately 30 g of cells was sus-
pended in 140 ml of 50 mM Tris  HCl buffer, pH 7.8 (buffer A), containing
protease inhibitors (Complete protease inhibitor cocktail tablets; Boehringer
Mannheim) and lysozyme (0.2 mg ml1). Cells were disrupted by sonication, and
cell debris was removed by centrifugation (at 48,000  g for 30 min). The
supernatant was incubated with 1% (wt/vol) streptomycin sulfate and centrifuged
at 48,000  g for 30 min. The resulting supernatant was dialyzed against buffer
A and loaded onto a Q-Sepharose Fast Flow column (GE Healthcare) preequili-
brated with buffer A, and the absorbed material was eluted with a linear gradient
from 0 to 0.5 M NaCl. Fractions containing M. tuberculosis DHQS were pooled
and loaded onto a HiLoad 16/10 phenyl-Sepharose (GE Healthcare) column,
and protein elution was achieved with a linear gradient of 1 to 0 M ammonium
sulfate. The fractions containing M. tuberculosis DHQS were pooled and con-
centrated down to 10 ml using an Amicon ultrafiltration cell (molecular weight
cutoff, 30,000). The sample was loaded onto a Sephacryl S-200 HR column (GE
Healthcare) and eluted with buffer A. The homogeneous recombinant protein
was stored in a saturated ammonium sulfate solution. Protein expression and all
purification steps were analyzed by SDS-PAGE, and protein concentrations were
determined by the method of Bradford (5) using the Bio-Rad Laboratories
protein assay kit.
N-terminal amino acid sequencing. The N-terminal amino acid residues of
homogeneous recombinant M. tuberculosis DHQS were identified by automated
Edman degradation sequencing using a PPSQ 21A gas-phase sequencer
(Shimadzu).
Mass spectrometry analysis. The homogeneity of the protein preparation was
assessed by ESI-MS with some adaptations (8). Samples were analyzed on a
triple quadrupole mass spectrometer (model QUATTRO II) equipped with a
standard ESI probe (Micromass, Altrincham, United Kingdom) and adjusted to
a flow rate of ca. 250 l min1. The source temperature (80°C) and needle
voltage (3.6 kV) were maintained constant throughout the collection of experi-
mental data, applying a drying gas (nitrogen) flow of 200 liters h1 and a
nebulizer gas flow of 20 liters h1. The mass spectrometer was calibrated with
intact horse heart myoglobin and its typical cone voltage-induced fragments. The
molecular mass of the recombinant M. tuberculosis DHQS subunit was deter-
mined by ESI-MS, by adjusting the mass spectrometer to give a peak with a
half-height of 1 mass unit, and the sampling cone-to-skimmer lens voltage con-
trolling the transfer of ions to the mass analyzer was set to 38 V. About 50 pmol
(10 l) of each sample was injected into the electrospray transport solvent. The
ESI spectrum was obtained in the multichannel acquisition mode, with scanning
from 500 to 1,800 m/z at a scan time of 7 s. The mass spectrometer is equipped
with MassLynx and Transform software for data acquisition and spectrum han-
dling.
Genetic complementation. The EcoRI and HindIII (Boehringer Mannheim)
restriction sites were introduced into the aroB gene through a new round of PCR
amplification. The amplified fragment was cloned into the pKK223-3 expression
vector (NCCB 3190). Genetic complementation was performed using the mutant
E. coli strain AB2847 (Genetic Stock Center), whose aroB gene has been
knocked out. Two batches of solid medium were prepared, one lacking phenyl-
alanine, tyrosine, and tryptophan and the other supplemented with these aro-
matic compounds (Sigma) at final concentrations of 40 g ml1 each. The E. coli
mutant strain AB2847 was transformed with the recombinant plasmid, grown on
minimal medium agar plates (11) with 100 g ml1 ampicillin, either with or
without aromatic amino acid supplementation, at 37°C. For control experiments,
the E. coli mutant strain AB2847 was transformed with the pKK223-3 vector
lacking the M. tuberculosis aroB gene.
M. tuberculosis DHQS activity assay. Recombinant M. tuberculosis DHQS
protein was assayed in the forward direction in 50 mM Tris-HCl, pH 7.6, at 25°C.
Enzyme activity was measured by estimating the rate of inorganic phosphate (Pi)
release in solution using a continuous spectrophotometric coupled assay with
human purine nucleoside phosphorylase (PNP) and 2-amino-6-mercapto-7-
methylpurine ribonucleoside (MESG). This assay is based on the maximum
difference in absorbance at 360 nm between MESG and the purine base product
(2-amino-6-mercapto-7-methylpurine) produced by PNP-catalyzed phosphorol-
ysis of MESG (37). The PNP-coupled assay has been utilized to continuously
monitor Pi production catalyzed by a number of enzymes (27, 28, 29). Typically,
a 500-l assay mixture contained 0.5 mM MESG, 0.5 U PNP, 0.250 mM DAHP
(Toronto Research Chemicals Inc.), and 0.250 mM NAD (Sigma). All compo-
nents were mixed and incubated for 10 min to consume any endogenous Pi that
might be present in the DAHP solution, and reactions were initiated by addition
of M. tuberculosis DHQS (stock solution, 1.7 mg ml1).
RESULTS AND DISCUSSION
The M. tuberculosis genome has a high content of cytosine
and guanine bases, approximately 65.6% (9). Although higher
temperatures are usually used for DNA denaturation of these
types of genomes, the aroB gene was amplified using standard
PCR conditions. However, amplification of the aroB gene from
M. tuberculosis H37Rv genomic DNA was achieved only in the
presence of 10% DMSO in the reaction mixture. DMSO is a
cosolvent that improves the denaturation of GC-rich DNA
(38) and facilitates PCR extension by DNA polymerase
through DNA secondary structures that may hinder amplifica-
tion (31). The PCR fragment was inserted into the pET23a()
expression vector between the NdeI and BamHI restriction
sites, and DNA sequencing of the entire aroB structural gene
confirmed the identity of the gene and the absence of PCR-
introduced mutations.
Recombinant M. tuberculosis DHQS was overexpressed in
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its soluble form in E. coli BL21(DE3) host cells in the absence
of IPTG induction (Fig. 3). It has been shown previously that
lac-controlled systems, including the pET system, could have
high-level protein expression in the absence of inducer. It has
been proposed that leaky protein expression is a property of
the lac-controlled system as cells approach stationary phase in
complex medium and that cyclic AMP, acetate, and low pH are
required to achieve high-level expression in the absence of
IPTG induction, which may be part of a general cellular re-
sponse to nutrient limitation (19). Accordingly, a number of
reports have described similar results (24, 28, 32, 33). SDS-
PAGE showed expression of a soluble protein with a molecular
size consistent with that expected for M. tuberculosis DHQS
(38.1 kDa) (Fig. 3). M. tuberculosis DHQS was purified to
homogeneity from a crude extract by using a protocol including
anionic exchange, followed by hydrophobic interaction and
elution on gel filtration columns, yielding 5 mg of recombinant
protein per liter of cell culture. No contaminants were detected
by SDS-PAGE analysis (Fig. 4). Homogeneous recombinant
protein was stored in an 85% (NH4)2SO4 saturated solution.
The molecular mass of the M. tuberculosis DHQS subunit
was determined by ESI-MS to be 38,135.70 Da, consistent with
the posttranslational removal of an N-terminal methionine res-
idue from the full-length gene product (predicted mass,
38,266.00 Da). The ESI-MS result revealed no peak at the
expected mass for E. coli DHQS (38,880.90 Da). The first 18
amino-terminal amino acid residues of the purified recombi-
nant protein were determined to be TDIGAPVTVQVAVD
PPYP by Edman degradation, thereby unambiguously identi-
fying M. tuberculosis DHQS and confirming removal of the
N-terminal methionine residue from it.
To confirm the correct assignment to the structural gene
encoding M. tuberculosis DHQS, the biological activity of re-
combinant M. tuberculosis DHQS was probed by genetic
complementation using E. coli mutants lacking the aroB gene
(E. coli AB2847). Although strain AB2847 is not able to grow
in minimal medium due to the lack of the DHQS-encoding
gene, supplementation of minimal medium with phenylala-
nine, tyrosine, and tryptophan enables the cells to grow. On the
other hand, the expression of the target protein in pKK233-3 is
not controlled by T7 RNA polymerase as in the pET system.
Therefore, since E. coli strain AB2847 does not have a copy of
T7 RNA polymerase in its genome, a different plasmid must be
used to express M. tuberculosis DHQS in this E. coli mutant.
Accordingly, PCR amplification was performed using the re-
combinant plasmid pET23a()::aroB as a template to sub-
clone the M. tuberculosis aroB fragment into the pKK233-3
expression vector, containing EcoRI and HindIII restriction
sites. Transformed E. coli AB2847 harboring the recombinant
pKK223-3::aroB plasmid was able to grow in minimal medium
without aromatic amino acid supplements, whereas E. coli
AB2847 transformed with the pKK223-3 vector lacking the M.
tuberculosis aroB gene was able to grow only in minimal me-
dium containing aromatic amino acid supplements (Fig. 5).
These results demonstrate that the M. tuberculosis aroB gene
encodes an active DHQS enzyme that is responsible for the
auxotrophic phenotype and consequently probes the function-
ality of the recombinant protein, which also functions in E. coli.
It has been reported previously that the M. tuberculosis aroB
gene codes for a DHQS activity in E. coli (18). However,
Garbe et al. transformed an E. coli strain lacking the aroB gene
with a recombinant plasmid containing a 3.4-kb DNA fragment
that encompassed aroD (named aroQ by Garbe et al.) and aroB
genes as well as sequences of unknown function (18). Accord-
ingly, to the best of our knowledge, here we describe the first
experimental evidence for the correct assignment to the open
reading frame of the aroB coding sequence.
In B. subtilis, DHQS has been purified in association with
chorismate synthase and NADPH-dependent flavin reductase.
The enzyme was active only when associated with chorismate
synthase, whereas the flavin reductase could be separated from
the complex with retention of DHQS activity (20). DHQS,
chorismate synthase, and flavin reductase form a trifunctional
enzyme complex, and chorismate synthase is required for
DHQS activity. The complex can be dissociated into flavin
reductase and chorismate synthase with the loss of DHQS
activity (20). Interestingly, in the work reported here, M. tu-
FIG. 3. Analysis of DHQS expression by SDS-PAGE. Lanes:
1, insoluble fraction of E. coli BL21(DE3) transformed with
pET23a()::aroB; 2, protein molecular size standards (200, 97, 68, 43,
29, and 18 kDa) (Gibco); 3, insoluble fraction of E. coli BL21(DE3)
transformed with pET23a() (control); 4, soluble fraction of E. coli
BL21(DE3) transformed with pET23a() (control); 5, soluble fraction
of E. coli BL21(DE3) transformed with pET23a()::aroB.
FIG. 4. Analysis of purification steps of DHQS by SDS-PAGE.
Lanes: 1, crude extract after dialysis; 2, protein molecular size stan-
dards (97, 68, 43, 29, 18, and 14 kDa) (Gibco); 3 through 5, DHQS
after elution on Q-Sepharose Fast Flow, phenyl-Sepharose, and
Sephacryl S-200 HR columns, respectively.
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berculosis DHQS was purified as a single protein with no other
associated protein, which suggests that the quaternary struc-
ture is homomeric, like that of E. coli DHQS (3). However, it
is also conceivable that M. tuberculosis DHQS requires other
enzymes for activity that were not observed in the homoge-
neous recombinant protein because they were not present at
concentrations comparable to that of the overexpressed pro-
tein. Accordingly, increasing amounts of homogeneous M. tu-
berculosis DHQS were added to the reaction mixture, and
enzyme activity was measured. The M. tuberculosis DHQS en-
zyme activity was linearly dependent on the volume of sample
added to the reaction mixture (Fig. 6), thereby showing that M.
tuberculosis DHQS does not require other enzymes for activity
and is thus homomeric. These results also show that true initial
velocities are being measured.
The amino acid sequence comparison between M. tubercu-
losis DHQS and DHQSs from other organisms showed highly
conserved residues (Fig. 7), which may be involved in protein
function and activity, either directly or indirectly, by mainte-
nance of an appropriate conformation (15). Even though bac-
terial DHQSs are smaller than their eukaryotic counterparts,
the degree of homology does not diverge among prokaryotes
(either gram-positive or gram-negative bacteria) and eu-
karyotes. In eukaryotic organisms such as N. crassa, A. nidu-
lans, and Saccharomyces cerevisiae, the DHQS reaction is the
first of five sequential steps in the shikimate pathway that are
FIG. 5. Analysis of functional complementation. (Left) Minimal medium agar plates. Sector A, AB2847 transformed with pKK223-3 (negative
control); sectors B, C, and D, AB2847 transformed with pkk223-3::aroB. (Right) Minimal medium supplemented with phenylalanine, tyrosine, and
tryptophan. Sector E, AB2847 transformed with pKK223-3 (negative control); sectors F, G, and H, AB2847 transformed with pkk223-3::aroB.
FIG. 6. Linear dependence of M. tuberculosis DHQS activity on homogeneous recombinant protein volume. The rates of Pi release due to M.
tuberculosis DHQS enzyme activity were followed in the forward direction by continuously monitoring the increase in the concentration of
2-amino-6-mercapto-7-methylpurine at 360 nm produced by phosphorolysis of MESG catalyzed by PNP in a coupled assay.
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catalyzed by the arom enzyme complex (21). The multifunc-
tional complex enzymes have spatially distinct catalytic sites for
DHQS and the four subsequent enzymes. Moreover, eukary-
otic DHQSs have a nonconserved insertion (of different
lengths in different species) in a downstream domain, which
may be important for their assembly as a multifunctional com-
plex. M. tuberculosis DHQS shows 25 to 37% overall identity
and 52 to 69% similarity with DHQSs from E. coli, Salmonella
enterica serovar Typhimurium, B. subtilis, A. nidulans, and
Staphylococcus aureus. Amino acid sequence comparison (Fig.
7) indicates the conservation of Lys157, Asn167, Arg269, and
Asn273 (according to M. tuberculosis aroB gene numbering).
These conserved amino acid residues have been shown to be
involved in conformational changes upon substrate binding to
the enzyme active site in S. aureus DHQS and A. nidulans
DHQS (26).
The chemical reaction catalyzed by DHQS (Fig. 2) is mech-
anistically unusually diverse for a single enzyme and includes
(i) the oxidation of the secondary alcohol at C-5 of DAHP, (ii)
the -elimination of inorganic phosphate across C-6 and C-7,
(iii) the reduction of the resulting eneone at C-5, (iv) the ring
opening of the enol pyranose, and (v) the final intramolecular
aldol-like reaction that produces 3-dehydroquinate (3, 25). De-
spite the fact that the bioavailability of Zn2 in nature is much
greater than that of Co2, the Co2 form of the enzyme has
been reported to be more stable and has a higher specific
activity than the Zn2 form (23). However, the mode of action
of M. tuberculosis DHQS is still unknown, and the availability
of a homogeneous enzyme will allow mechanistic and struc-
tural studies to be carried out. Expression of functional pro-
teins in soluble form has been identified as an important bot-
tleneck in efforts to determine the biological activity and
crystal structure of M. tuberculosis proteins (36). Moreover,
protein purification has become an important asset for any
research group, since demand for homogeneous proteins has
been increasing (7).
In this report, we present the cloning, purification, and ge-
netic complementation of the aroB gene from M. tuberculosis.
The availability of functional homogeneous M. tuberculosis
DHQS will provide protein in quantities necessary for both
X-ray crystal structure determination and studies on the mode
of action of the enzyme by steady-state and pre-steady-state
kinetics to allow the rational design of antimycobacterial
agents. Moreover, the availability of homogeneous M. tubercu-
losis DHQS will allow immobilization on a solid support in
order to screen for new chemical entities from plant-derived
chemical compound libraries to identify antituberculosis
agents as described elsewhere (2).
FIG. 7. Comparison of prokaryotic and eukaryotic DHQS amino acid sequences. Shown are DHQS sequences for Escherichia coli (Ec) (362
residues), Salmonella serovar Typhimurium (St) (362 residues), Mycobacterium tuberculosis (Mt) (362 residues), Aspergillus nidulans (An) (403
residues), Bacillus subtilis (Bs) (362 residues), and Staphylococcus aureus (Sa) (354 residues). The conserved amino acid residues Lys157, Asn167,
Arg269, and Asn273 in M. tuberculosis DHQS (corresponding to amino acid residues Lys136, Asn146, Arg235, and Asn239 in S. aureus DHQS [26])
are boxed.
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